Clinical Trial: NCT01715285
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2025-02-04 |
Study Overview
Brief Summary
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
Official Title
Conditions
Intervention / Treatment
- Drug: Abiraterone acetate
- Drug: Prednisone
- Other: Androgen deprivation therapy (ADT)
- Drug: Abiraterone acetate Placebo
- Drug: Prednisone Placebo
Other Study ID Numbers
- CR100900
- 212082PCR3011
- 2012-002940-26
- U1111-1135-7146
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Janssen Research & Development, LLC |
| Information Provided By: | Janssen Research & Development, LLC |
| Last Update Posted: | 2025-02-04 |
Study Overview
Brief Summary
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
Official Title
Conditions
Intervention / Treatment
- Drug: Abiraterone acetate
- Drug: Prednisone
- Other: Androgen deprivation therapy (ADT)
- Drug: Abiraterone acetate Placebo
- Drug: Prednisone Placebo
Other Study ID Numbers
- CR100900
- 212082PCR3011
- 2012-002940-26
- U1111-1135-7146